KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis. PMID 40468999 · Acta Oncol · 2025-Jun-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. PMID 40305708 · N Engl J Med · 2025-Jun-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Local therapy for oligometastatic prostate cancer. PMID 40088427 · Jpn J Clin Oncol · 2025-Jun-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113. PMID 40052520 · Jpn J Clin Oncol · 2025-Jun-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study). PMID 39997358 · Jpn J Clin Oncol · 2025-Jun-05 The record describes a Phase III randomized trial protocol for a maintenance study in follicular lymphoma, but the abstract does not report any time-to-event efficacy results. It is a protocol/registration summary without primary or secondary outcome data.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study. PMID 40542585 · Oncologist · 2025-Jun-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy. PMID 40488582 · J Crohns Colitis · 2025-Jun-04 The record describes a non-oncology disease (ulcerative colitis) and does not report a primary/key secondary time-to-event efficacy endpoint for human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of 15- or 25-min intermittent Pringle maneuver on early recurrence of hepatocellular carcinoma after hepatectomy: a protocol for a randomized controlled trial. PMID 40468382 · Trials · 2025-Jun-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A randomized controlled trial exploring the effect of placement versus nonplacement of a drainage tube around the cervical anastomosis in McKeown esophagectomy. PMID 40467612 · Sci Rep · 2025-Jun-04 The trial is a surgical RCT without a drug intervention and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE study). PMID 40467307 · BMJ Open · 2025-Jun-04 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). PMID 40243842 · J Crohns Colitis · 2025-Jun-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies. PMID 40461265 · RMD Open · 2025-Jun-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Consensus process to agree upon surgical quality assurance processes within a pragmatic, multicentre randomised clinical trial comparing targeted axillary dissection and axillary node clearance: the TADPOLE-TOGETHER project. PMID 40461151 · BMJ Open · 2025-Jun-03 The record is a protocol for a surgical randomized controlled trial in oncology (breast cancer), but it does not report results of a drug-containing intervention with a time-to-event efficacy endpoint. The intervention is surgical, and the publication is a protocol describing a quality assurance process, not an original result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Midurethral Sling vs OnabotulinumtoxinA in Females With Urinary Incontinence: The MUSA Randomized Clinical Trial. PMID 40323617 · JAMA · 2025-Jun-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): A phase III crossover trial. PMID 40311506 · Eur J Cancer · 2025-Jun-03 The study is a phase III, randomized, oncology, human, drug-intervention trial with original results. However, it is ineligible because the prespecified efficacy endpoints are response rates (categorical outcomes), not time-to-event outcomes as required by the cohort definition.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. PMID 40306121 · Eur J Cancer · 2025-Jun-03 The record describes a pooled analysis of two prior Phase III trials, evaluating a prognostic factor (relative dose intensity). It is not the primary or secondary result report of a single randomized trial. The intervention (FOLFOXIRI vs. doublets) was randomized in the parent trials, but this analysis is a post-hoc/prognostic subgroup analysis, not the original trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized Control Trial of Two Interventions Compared with Usual Care for Increasing Cervical Cancer Screening among Women Living in the Rural Midwest. PMID 40197927 · Cancer Epidemiol Biomarkers Prev · 2025-Jun-03 The study is an oncology-related randomized trial, but it does not meet the key eligibility criteria: it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) and does not involve a drug-containing intervention (comparing a DVD/patient navigation intervention vs. usual care).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study. PMID 40100121 · Clin Cancer Res · 2025-Jun-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis. PMID 39861972 · J Bone Miner Res · 2025-Jun-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Interaction effect of comorbid depression and proactive positivity coping strategy on the 1-year survival of patients with advanced cancer: a nationwide multicentre study in South Korea. PMID 40457290 · BMC Psychiatry · 2025-Jun-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Co-Designing an Infant Early Childhood Mental Health Mobile App for Early Childhood Education Teachers' Professional Development: Community-Based Participatory Research Approach. PMID 40456138 · JMIR Form Res · 2025-Jun-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative study of different treatment modalities for melasma: introducing a novel nanotechnology-based tranexamic acid microemulsion. PMID 40455320 · Arch Dermatol Res · 2025-Jun-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A home-based 12-week chair exercise intervention for older adults with advanced cancer receiving chemotherapy: a randomized pilot feasibility trial. PMID 40455316 · Support Care Cancer · 2025-Jun-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
HPV genotyping agreement between paired cervical cytological sample and biopsy across lesion severity and vaccination. PMID 40452051 · Virol J · 2025-Jun-02 The record describes a diagnostic agreement study from an ancillary analysis within a randomized trial. It lacks a therapeutic drug intervention and does not report a time-to-event efficacy endpoint (OS, PFS, etc.) as the primary/key secondary outcome. The phase and randomization are noted, but the core study question is not eligible per the cohort definition.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age. PMID 40119775 · J Infect Dis · 2025-Jun-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer. PMID 40041932 · Cancer Prev Res (Phila) · 2025-Jun-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal. PMID 39478672 · J Infect Dis · 2025-Jun-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis. PMID 40465504 · J Drugs Dermatol · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial. PMID 40452026 · BMC Cancer · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness of a community health advisor colorectal cancer screening educational intervention on stool test completion in an African American primary care patient population: a pragmatic randomized controlled trial. PMID 40450376 · BMC Glob Public Health · 2025-Jun-01 Study is a randomized controlled trial in oncology (colorectal cancer screening) with human subjects and reports primary results. However, it is excluded because: 1) The intervention is a non-drug educational/community health advisor program, not a drug-containing intervention. 2) The primary efficacy endpoint is the proportion completing stool test at 12 months (a binary outcome), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, nor are Kaplan-Meier curves or hazard ratios reported. The trial registration number is provided but no phase is explicitly stated.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized controlled trial reporting guidelines should be updated to include information on subsequent treatments. PMID 40440214 · Cancer · 2025-Jun-01 The record is an editorial/commentary advocating for updated reporting guidelines, not an original report of a randomized trial with results. It discusses oncology trials and time-to-event endpoints (e.g., PFS2) but does not present primary or secondary efficacy data from a specific Phase III or definitive trial. It lacks explicit human trial phase information and drug intervention details for a specific study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist. PMID 40423237 · Endocr Connect · 2025-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma. PMID 40338596 · JAMA Ophthalmol · 2025-Jun-01 The record describes a phase 3b case series study characterizing ocular side effects of belantamab mafodotin in multiple myeloma patients. While it is an oncology study with a drug intervention in humans and phase 3/3b, it is non-randomized and its primary endpoint is pathologic characterization of corneal changes, not a time-to-event efficacy outcome. Therefore, it does not meet the eligibility criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial. PMID 40257755 · JAMA Intern Med · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial. PMID 40244574 · JAMA Oncol · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections. PMID 40233296 · Pediatr Infect Dis J · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial. PMID 40136309 · JAMA Cardiol · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. PMID 40117446 · Anesthesiology · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
VERY EARLY USE OF ESMOLOL IN HYPERKINETIC SEPTIC SHOCK PATIENTS WITH PERSISTENT TACHYCARDIA: A RANDOMIZED CONTROLLED PILOT STUDY. PMID 40101954 · Shock · 2025-Jun-01 The record describes a randomized controlled pilot study in septic shock (non-oncology) evaluating esmolol for heart rate control. It is not a trial of human malignant neoplasm, does not report a Phase III/IIIb or Phase II/III trial, and its primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nasal biomarker inflammatory profile in response to intranasal corticosteroids in pediatric obstructive sleep apnea syndrome. PMID 40051199 · J Clin Sleep Med · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. PMID 40042880 · JAMA Cardiol · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial. PMID 40037556 · Rheumatology (Oxford) · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Abatacept and the risk of malignancy: a meta-analysis across disease indications. PMID 39992258 · Rheumatology (Oxford) · 2025-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab. PMID 39985454 · Rheumatology (Oxford) · 2025-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial. PMID 39972543 · J Acquir Immune Defic Syndr · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial. PMID 39922319 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer. PMID 39922318 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study. PMID 39918968 · Rheumatology (Oxford) · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial. PMID 39914555 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 The study is a Phase III randomized trial with time-to-event endpoints in oncology, but the intervention is radiation therapy (hypofractionated vs. conventional), not a drug-containing intervention as required by the criteria.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT). PMID 39862898 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 The trial compares radiation therapy techniques (standard vs. dose-painted RT), not a drug intervention. While concurrent chemotherapy is given in both arms, it is standard background therapy, not the tested drug intervention. The phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -